Response from Marc, page-19

tuts ,at an estimate , approximately $15million dollars in kitty at end of 2nd quarter,,and possibly churning approximately $7 odd million a quarter ,leaves about 2 more quarters of cash without the touted GSK milestone payment and current raise,for mine ,not great again raising on lows but a necessary move. I think it was the blow out in Apaic time line that bought about the cap raise,as it was only a month or 2 ago ,trial results were being touted by the company to be released in q4 2019.Hence the capital shortfall and subsequent raise.